Antitumour compositions containing taxane derivatives

Abstract

Antitumor combinations consisting of taxol or Taxotere or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.

1 . Combinations of taxol, Taxotere and their derivatives with at least one substance which is therapeutically useful in the treatment of neoplastic diseases.  
     
     
         2 . Combinations of Taxotere with alkylating agents, antimetabolites, spindle poisons, epidophyllotoxins, antibiotics, enzymes, topoisomerase inhibitors, various compounds chosen from procarbazizne, mitoxantrone or platinum coordination complexes, biological response modifiers or growth factor inhibitors.  
     
     
         3 . Combinations according to  claim 2 , characterized in that the alkylating agents are chosen from cyclophosphamide, ifosfamide, melphalan, hexamethylmelamine, thiotepa or dacarbazine.  
     
     
         4 . Combinations according to  claim 2 , characterized in that the antimetabolites are chosen from 5-fluorouracil, cytarabine and folic acid analogues chosen from methotrexate, idatrexate and trimetrexate.  
     
     
         5 . Combinations according to  claim 2 , characterized in that the spindle poisons are chosen from vinca alkaloids, their synthetic or semi-synthetic analogues, or estramustine or taxoids.  
     
     
         6 . Combinations according to  claim 2 , characterized in that the epidophyllotoxins are chosen from etoposide and teniposide.  
     
     
         7 . Combinations according to  claim 2 , characterized in that the antibiotics are chosen from daunorubicin, doxorubicin, bleomycin and mitomycin.  
     
     
         8 . Combinations according to  claim 2 , characterized in that the enzyme is L-asparaginase.  
     
     
         9 . Combinations according to  claim 2 , characterized in that the topoisomerase inhibitors are chosen from camptothecin and its derivatives chosen from CPT-11 and topotecan and pyridobenzoindole derivatives.  
     
     
         10 . Combinations according to  claim 2 , characterized in that the various compounds are chosen from procarbazine, mitoxantrone and platinum coordination complexes chosen from cisplatin and carboplatin.  
     
     
         11 . Combinations according to  claim 2 , characterized in that the biological response modifiers and growth factor inhibitors are chosen from interferons and interleukins.  
     
     
         12 . Combinations according to one of  claims 1  to  11 , characterized in that they contain, in addition, growth factors of the haematopoietic type.  
     
     
         13 . Combinations according to one of  claims 1  to  12 , characterized in that they contain from 10 to 90% by weight of taxol, Taxotere or their analogues.  
     
     
         14 . Products containing Taxotere or their analogues and at least one substance which is therapeutically useful, as defined in one of  claims 1  to  12 , in the treatment of neoplastic diseases, as a combined preparation for use simultaneously, separately or spaced out over a period of time in anticancer therapy.